Characteristic | Event=any recurrence within 5 years | Event=non-vaginal recurrence within 5 years | ||||||
Overall population | After exclusion of patients with presence of LVSI | Overall population | After exclusion of patients with presence of LVSI | |||||
Adjusted HR (95% CI) | P value | Adjusted HR (95% CI) | P value | Adjusted HR (95% CI) | P value | Adjusted HR (95% CI) | P value | |
Adjusted model No 1 | ||||||||
SLN node status | 0.049 | 0.02 | ||||||
Node negative | Reference | Reference | ||||||
ITC | 3.02 (1.01 to 9.08) | 4.51 (1.31 to 15.57) | ||||||
LVSI | <0.01 | 0.02 | ||||||
No | Reference | Reference | ||||||
Yes | 10.24 (3.06 to 34.27) | 6.75 (1.32 to 34.46) | ||||||
Adjusted model No 2 | ||||||||
SLN node status | <0.01 | 0.09 | <0.01 | 0.03 | ||||
Node negative | Reference | Reference | Reference | Reference | ||||
ITC | 4.19 (1.51 to 11.61) | 3.00 (0.85 to 10.60) | 5.27 (1.64 to 16.97) | 4.47 (1.21 to 16.60) | ||||
Grade | 0.01 | 0.02 | 0.03 | 0.048 | ||||
1 | Reference | Reference | Reference | Reference | ||||
2 | 3.01 (1.28 to 7.12) | 3.04 (1.17 to 7.91) | 2.99 (1.08 to 8.29) | 3.02 (1.01 to 9.04) |
ITC, isolated tumor cell; LVSI, lymphovascular space invasion; SLN, sentinel lymph node.